Fluciclovine PET/CT Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/CT for active surveillance of patients with clinically established low-risk prostate cancer. Fluciclovine PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/MRI for active surveillance of patients with clinically established low-risk prostate cancer. Fluoride PET/CT Whole Body There is limited evidence to support the use of fluoride PET/CT for active surveillance of patients with clinically established low-risk prostate cancer. Pretreatment Detection of Prostate Cancer MRI Abdomen and Pelvis Without and With IV Contrast There is limited evidence to support the use of MRI abdomen and pelvis without and with IV contrast for active surveillance of patients with clinically established low-risk prostate cancer. MRI Abdomen and Pelvis Without IV Contrast There is limited evidence to support the use of MRI abdomen and pelvis without IV contrast for active surveillance of patients with clinically established low-risk prostate cancer. MRI Pelvis Without and With IV Contrast There has been a substantial increase in the role of MRI in active surveillance in terms of detecting/predicting disease progression and identifying targets amenable for biopsy. In a meta-analysis of 43 studies (6,605 patients), the sensitivity and negative predictive value of predicting disease reclassification were 0.60 and 0.75 using 1.5T scanners and 0.81 and 0.78 using 3.0T scanners [81]. In addition, several studies have shown that MRI is at least equivalent or superior to systematic TRUS-guided biopsies in identifying pathological progression during follow- up in patients on active surveillance [82-84].
Pretreatment Detection Surveillance and Staging of Prostate Cancer. Fluciclovine PET/CT Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/CT for active surveillance of patients with clinically established low-risk prostate cancer. Fluciclovine PET/MRI Skull Base to Mid-Thigh There is limited evidence to support the use of fluciclovine PET/MRI for active surveillance of patients with clinically established low-risk prostate cancer. Fluoride PET/CT Whole Body There is limited evidence to support the use of fluoride PET/CT for active surveillance of patients with clinically established low-risk prostate cancer. Pretreatment Detection of Prostate Cancer MRI Abdomen and Pelvis Without and With IV Contrast There is limited evidence to support the use of MRI abdomen and pelvis without and with IV contrast for active surveillance of patients with clinically established low-risk prostate cancer. MRI Abdomen and Pelvis Without IV Contrast There is limited evidence to support the use of MRI abdomen and pelvis without IV contrast for active surveillance of patients with clinically established low-risk prostate cancer. MRI Pelvis Without and With IV Contrast There has been a substantial increase in the role of MRI in active surveillance in terms of detecting/predicting disease progression and identifying targets amenable for biopsy. In a meta-analysis of 43 studies (6,605 patients), the sensitivity and negative predictive value of predicting disease reclassification were 0.60 and 0.75 using 1.5T scanners and 0.81 and 0.78 using 3.0T scanners [81]. In addition, several studies have shown that MRI is at least equivalent or superior to systematic TRUS-guided biopsies in identifying pathological progression during follow- up in patients on active surveillance [82-84].